Trifluoroacetic acid → HCID 178432926、化合物
反応式
C(OC([N:8]1[CH2:13][CH2:12][N:11]([C:14]2[CH:19]=[CH:18][C:17]([C:20]3[NH:42][C:23]4=[N:24][CH:25]=[C:26]([Br:41])[C:27]([N:28]5[CH2:33][CH2:32][N:31]([CH2:34][C:35]6[N:36]=[C:37]([CH3:40])[S:38][CH:39]=6)[CH2:30][CH2:29]5)=[C:22]4[N:21]=3)=[CH:16][CH:15]=2)[CH2:10][CH2:9]1)=O)(C)(C)C.C(O)(C(F)(F)F)=O>C(Cl)Cl>[Br:41][C:26]1[C:27]([N:28]2[CH2:29][CH2:30][N:31]([CH2:34][C:35]3[N:36]=[C:37]([CH3:40])[S:38][CH:39]=3)[CH2:32][CH2:33]2)=[C:22]2[N:21]=[C:20]([C:17]3[CH:18]=[CH:19][C:14]([N:11]4[CH2:10][CH2:9][NH:8][CH2:13][CH2:12]4)=[CH:15][CH:16]=3)[NH:42][C:23]2=[N:24][CH:25]=1参加物
実験手順
tert-Butyl-4-(4-(6-bromo-7-(4-((2-methylthiazol-4-yl)methyl)piperazin-1-yl)-3H-imidazo[4,5-b]pyridin-2-yl)phenyl)piperazine-1-carboxylate (0.022 g, 0.033 mmol) was suspended in DCM (2.0 mL) and the mixture cooled in an ice bath. TFA (0.5 mL) was added and the resulting solution was allowed to warm up to room temperature and stirred for 2 h. The mixture was passed through an SCX column (5 g), the filtrate collected and the solvent removed in vacuo to give the title compound as a solid (0.016 g, 86%); 1H-NMR (500 Mz, DMSO-d6): δ 2.61-2.70 (m, 7H), 2.81-2.89 (m, 4H), 3.15-3.22 (m, 4H), 3.60-3.68 (m, 6H), 7.03 (d, J=9.0 Hz, 2H, ArH, C6H4), 7.32 (s, 1H, thiazole 5-H), 8.02 (d, J=9.0 Hz, 2H, ArH, C6H4), 8.17 (s, 1H, imidazo[4,5-b]pyridine 5-H); LC (Method B)-MS (ESI, m/z) 2.23 min—553/555 [(M+H)+, Br isotopic pattern]. ESI-HRMS: Found: 553.1522, calculated for C25H30BrN8S (M+H)+: 553.1498.
後処理
- temperaturethe mixture cooled in an ice bath
- customthe filtrate collected
- customthe solvent removed in vacuo
出典と根拠
- ORDレコード
- ord-0a174505ef054c12854574756dd0ab5d
- 出典データセット
- uspto-grants-2012_01
- 特許番号
- US08088761B2
反応ノート
読み込み中…